Jinwon Life Sciences Subsidiary VGXI Appoints Jeff Whitmore as CCO

Jinwon Life Sciences announced on the 1st that it has appointed Jeff Whitmore as the Chief Commercial Officer (CCO) of its subsidiary VGXI, a plasmid DNA and RNA pharmaceutical contract development and manufacturing organization (CDMO) company that complies with current Good Manufacturing Practice (cGMP) standards for excellent pharmaceutical manufacturing and quality control.

Newly appointed CCO Whitmore will oversee all sales operations at VGXI’s headquarters and new state-of-the-art manufacturing facility located in the DaySon Technology Park in Conroe, Texas, USA.

Whitmore is a bio-industry expert with over 25 years of global sales and marketing experience. He has held leadership roles in sales at various life sciences companies such as Bio-Rad, served as Chief Commercial Officer (CCO) at Genegen, and was Vice President of Sales Operations at TriLink Biotechnology, a global leader in nucleic acid and mRNA solutions.

The company emphasized that with VGXI’s expanded new manufacturing facility to meet the rapidly growing global demand for vaccines, immunotherapies, cell and gene therapies, the CDMO business will be fully launched through strategic marketing.

Youngkeun Park, CEO of Jinwon Life Sciences, said, “Following the recent appointment of Jim Smith as VGXI’s Chief Accounting Officer (CAO), we have recruited Jeff Whitmore, a talented professional who led successful product value positioning and company growth during his tenure at TriLink, as CCO. As part of VGXI’s strategy to strengthen sustainable growth momentum, we will enhance business competitiveness in the global CDMO market through securing specialized personnel and achieve visible sales results.”